scholarly journals Lume-Colon 1: Double-Blind, Randomised Phase III Study of Nintedanib (Bibf 1120) Plus Best Supportive Care (Bsc) Versus Placebo Plus Bsc in Patients (Pts) with Refractory Colorectal Cancer

2014 ◽  
Vol 25 ◽  
pp. iv208 ◽  
Author(s):  
E. Van Cutsem ◽  
J. Tabernero ◽  
T. Yoshino ◽  
M. Sassi ◽  
Z. Oum'Hamed-Mansour ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Supportive Care ◽  
Best Supportive Care ◽  
Phase Iii ◽  
Double Blind ◽  
Phase Iii Study ◽  
Bibf 1120

scholarly journals FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer

2021 ◽  
Author(s):  
Arvind Dasari ◽  
Alberto Sobrero ◽  
James Yao ◽  
Takayuki Yoshino ◽  
William Schelman ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Supportive Care ◽  
Metastatic Colorectal Cancer ◽  
Kinase Inhibitor ◽  
Progression Free Survival ◽  
Best Supportive Care ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Phase Iii Study

Fruquintinib, a novel, highly selective, small-molecule tyrosine kinase inhibitor of VEGF receptors (VEGFRs)-1, -2 and -3, is approved in China for the treatment of metastatic colorectal cancer. FRESCO-2, a global, randomized, double-blind, placebo-controlled, Phase III study, is investigating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. Key inclusion criteria include: progression on or intolerance to TAS-102 and/or regorafenib; and prior treatment with approved chemotherapy, anti-VEGF therapy, and, if RAS wild-type, anti-EGFR therapy. Approximately 687 patients will be randomized 2:1 to fruquintinib plus best supportive care or placebo plus best supportive care. Primary and key secondary end points are overall survival and progression-free survival, respectively. FRESCO-2 is enrolling in the USA, Europe, Australia and Japan.

Sign in / Sign up

Export Citation Format

Share Document